In addition to providing excellent care, Memorial Sloan-Kettering is constantly working to improve treatment for prostate cancer. Our clinical trials enable us to deliver state-of-the-art care, and our physicians lead a large number of trials of innovative approaches to treatment for men at all clinical states of prostate cancer. These trials test new drugs and drug combinations, surgical and radiation therapy techniques, innovative diagnostic technologies, and strategies for preserving quality of life for men undergoing treatment.
Choosing Memorial Sloan-Kettering for your care may give you access to new treatment options before they are widely available elsewhere. Our experts can help to determine which clinical trials are right for you. For more information about our clinical trials, call our Physician Referral Service at 800-525-2225, or talk with your doctor.
Memorial Sloan-Kettering is the coordinating center for the Prostate Cancer Clinical Trials Consortium (PCCTC), a national organization that includes 13 leading academic centers. The PCCTC is engaged in the development of new medications and new combined-modality approaches against aggressive disease that will affect lifespan or quality of life. We have long been at the forefront of bringing needed new drugs to patients quickly. Our medical oncologists have leadership positions within the consortium and other national clinical trial groups focusing on prostate cancer, and created the infrastructure for the development and evaluation of new prostate cancer drugs.
The following prostate cancer clinical trials at Memorial Sloan-Kettering are currently enrolling new patients. To learn more about a study, choose from the list below.